---

• Zurich-Schlieren, Switzerland
• SIX: MOLN


• Contact:
  Petri Vainio
  
• IPO

Related News

• Molecular Partners Announces Collaboration with Novartis to develop two DARPin® Therapies Designed for Potential Use Against COVID-19
• Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin® Program
• Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi-Target Binding of DARPin® Proteins to Neutralize SARS-CoV-2 Virus
• Molecular Partners Announces Newly Nominated Board Members for Upcoming Annual Meeting
• Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized
• Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and
• Molecular Partners’ Strategic Partner Allergan Announced Today that EMA has Validated the Marketing
• Molecular Partners and Amgen Announce Strategic Collaboration in Immuno-Oncology
• Abicipar Phase 3 Data Presented at AAO Conference in Chicago:
• Molecular Partners and Astra Zeneca Announce Collaboration
• Molecular Partners’ Partner Allergan Exercises Options for Two DARPin Product Candidates
• Bill Burns Nominated for Election to Molecular Partners’ Board of Directors
• Molecular Partners Reveals Programs in Immuno-Oncology
• Molecular Partners Received a European Small and Mid-Cap Award
• Molecular Partners Wins European Biotechnica Award 2015
• Allergan Strengthens DARPin Development and Discovery Alliance with Molecular Partners
• Allergan and Molecular Partners Enter into an Exclusive Alliance
• Molecular Partners Comments on Allergan’s Progress in Phase IIa Retinal Disease Trial using anti-VEGF DARPin
• Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®
• Allergan and Molecular Partners Enter into an Exclusive License Agreement for MP0112 for the Treatment of Retinal Diseases
• Molecular Partners Reports Positive Results From its First Clinical Studies
• Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum
• Molecular Partners Secures CHF 46 million in Series B Financing Led by Essex Woodlands